58.48
10 X Genomics Inc stock is traded at $58.48, with a volume of 4.33M.
It is down -0.15% in the last 24 hours and up +36.86% over the past month.
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives operates from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).
See More
Previous Close:
$58.57
Open:
$58.43
24h Volume:
4.33M
Relative Volume:
1.34
Market Cap:
$7.42B
Revenue:
$638.78M
Net Income/Loss:
$-22.66M
P/E Ratio:
-335.32
EPS:
-0.1744
Net Cash Flow:
$122.18M
1W Performance:
+22.19%
1M Performance:
+36.86%
6M Performance:
+205.38%
1Y Performance:
+375.06%
10 X Genomics Inc Stock (TXG) Company Profile
Name
10 X Genomics Inc
Sector
Industry
Phone
(925) 401-7300
Address
6230 STONERIDGE MALL ROAD, PLEASANTON, CA
Compare TXG vs VEEV, BTSG, TEM, HQY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
TXG
10 X Genomics Inc
|
58.48 | 5.83B | 638.78M | -22.66M | 122.18M | -0.1744 |
|
VEEV
Veeva Systems Inc
|
236.58 | 31.59B | 3.32B | 941.65M | 1.64B | 5.6161 |
|
BTSG
Brightspring Health Services Inc
|
57.89 | 14.13B | 13.65B | 169.86M | 412.12M | 1.0758 |
|
TEM
Tempus Ai Inc
|
55.69 | 7.73B | 1.36B | -302.91M | -219.93M | -1.7182 |
|
HQY
Healthequity Inc
|
105.57 | 8.28B | 1.34B | 230.70M | 440.96M | 2.6695 |
10 X Genomics Inc Stock (TXG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-31-26 | Upgrade | William Blair | Mkt Perform → Outperform |
| Dec-11-25 | Downgrade | Citigroup | Buy → Neutral |
| Dec-02-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-11-25 | Initiated | Piper Sandler | Neutral |
| Feb-13-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Sep-03-24 | Initiated | Leerink Partners | Outperform |
| Jul-22-24 | Upgrade | Jefferies | Hold → Buy |
| Jul-18-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-10-24 | Downgrade | Deutsche Bank | Buy → Hold |
| Jun-27-24 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jun-25-24 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-03-24 | Resumed | Jefferies | Hold |
| May-01-24 | Downgrade | TD Cowen | Buy → Hold |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Dec-12-23 | Upgrade | BofA Securities | Underperform → Neutral |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| May-10-23 | Initiated | Barclays | Overweight |
| Mar-31-23 | Initiated | Stephens | Overweight |
| Feb-02-23 | Initiated | UBS | Neutral |
| Dec-14-22 | Initiated | Deutsche Bank | Buy |
| Aug-18-22 | Downgrade | Goldman | Neutral → Sell |
| Jul-25-22 | Initiated | Canaccord Genuity | Buy |
| Jul-15-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jul-15-22 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Sep-14-21 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-15-21 | Initiated | William Blair | Outperform |
| Dec-02-20 | Initiated | Goldman | Neutral |
| Sep-09-20 | Initiated | Morgan Stanley | Overweight |
| Jul-10-20 | Initiated | Stifel | Buy |
| Mar-05-20 | Initiated | Guggenheim | Buy |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Oct-07-19 | Initiated | BofA/Merrill | Buy |
| Oct-07-19 | Initiated | Cowen | Outperform |
| Oct-07-19 | Initiated | JP Morgan | Overweight |
| Sep-24-19 | Initiated | Evercore ISI | Outperform |
View All
10 X Genomics Inc Stock (TXG) Latest News
10x Genomics, Inc. (TXG) Stock Analysis: Navigating the High Valuation and Market Dynamics - DirectorsTalk Interviews
Is 10x Genomics Inc (TXG) Overvalued After 12.3% Rally? GF Value - GuruFocus
10x Genomics, Inc. (TXG) stock price, news, quote and history - Yahoo Finance UK
10x Genomics (NASDAQ:TXG) Trading Up 7.1%Time to Buy? - MarketBeat
TXG Stock Jumps As Earnings Beat Triggers Analyst Upgrades - stockstotrade.com
10X GENOMICS INC : CANACCORD GENUITY RAISES TARGET PRICE TO $60 FROM $50 - Bitget
10x Genomics Stock Jumps As Analysts Hike Price Targets - timothysykes.com
10X Genomics Inc (TXG) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Enterprise value to EBIT forward of 10x Genomics Inc Class A – BMV:TXG - TradingView
Analysts Offer Insights on Healthcare Companies: Arvinas Holding Company (ARVN), 10x Genomics (TXG) and Teleflex (TFX) - The Globe and Mail
TXG Jumps As 10x Genomics Price Targets Surge After Q2 Beat - timothysykes.com
10X Genomics Inc (TXG) Stock News Today - TradingKey
10x Genomics, Inc. Stock 12‑Month Price Target Raised to $47.23, Implies 4% Upside - TradingView
10x Genomics Q2 Earnings Call Highlights - MarketBeat
10x Genomics stock hits 52-week high at 50.36 USD - Investing.com
10x Genomics Q2 Earnings & Revenues Beat Estimates, Gross Margin Up - finance.yahoo.com
10X GENOMICS, INC. : JEFFERIES RAISES TARGET PRICE TO $53 FROM $40 - moomoo.com
10x Genomics, Inc. Q2 2026 Earnings Call Summary - finance.yahoo.com
10x Genomics (NASDAQ: TXG) grows consumables, ends Q2 with $502M cash - Stock Titan
10x Genomics, Inc. 2026: Revenue $151.04M, EPS ($0.14) — 10-Q Summary - TradingView
10x Genomics $TXG Shares Sold by Janus Henderson Group PLC - MarketBeat
TXG|10X Genomics Inc|Price:58.260|Chg%:+6.230 - TradingKey
Has 10x Genomics Inc (TXG) Missed Earnings Expectations with Q2 - GuruFocus
10x Genomics (NASDAQ:TXG) Posts Quarterly Earnings Results, Beats Expectations By $0.10 EPS - MarketBeat
Earnings call transcript: 10x Genomics tops Q2 2026 estimates, shares fall - Investing.com
Transcript : 10x Genomics, Inc., Q2 2026 Earnings Call, Aug 06, 2026 - marketscreener.com
10x Genomics Inc (TXG) Shares Fall 3.9% -- What GF Score of 58 T - GuruFocus
10x Genomics’s (NASDAQ:TXG) Q2 CY2026: Strong Sales, Full-Year Outlook Slightly Exceeds Expectations - finance.yahoo.com
10x Genomics (TXG) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates - finance.yahoo.com
10x Genomics (TXG) Reports Q2 Loss, Tops Revenue Estimates - finance.yahoo.com
10x Genomics falls 2% despite beating revenue estimates - Investing.com
10x Genomics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
(TXG) 10x Genomics Now Expects 2026 Revenue Range $610M-$630M, vs. FactSet Est of $613.7M - marketscreener.com
Q2 2026 10X Genomics Inc Earnings Call Transcript - GuruFocus
10x Genomics Q2 2026: Revenue $151.0M, Gross Margin 74%, Raises 2026 Revenue Guide - TradingView
10x Genomics: Q2 Earnings Snapshot - AOL.com
Earnings Flash (TXG) 10x Genomics, Inc. Reports Q2 Revenue $151.0M, vs. FactSet Est of $146.7M - marketscreener.com
10x Genomics (NASDAQ: TXG) swings to Q2 loss but lifts 2026 revenue guide - Stock Titan
10x Genomics Reports Second Quarter 2026 Financial Results - marketscreener.com
10x Genomics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
10X Genomics faces earnings test as revenue expected to decline By Investing.com - Investing.com Nigeria
10x Sued Over Spatial Genomics Patents by Caltech, Licensee (1) - Bloomberg Law News
10x Genomics (TXG) 10K Form and Latest SEC Filings 2026 - MarketBeat
10x Genomics (TXG) Reports Earnings Tomorrow: What To Expect - The Globe and Mail
10x Genomics, Inc. (TXG) - DirectorsTalk Interviews
58,083 Shares in 10x Genomics $TXG Acquired by Edgestream Partners L.P. - MarketBeat
Lazard Asset Management LLC Sells 45,761 Shares of 10x Genomics $TXG - MarketBeat
10x Genomics (TXG) Teams Up With Lausanne Hospital To Push Cancer Diagnostics Forward - finance.yahoo.com
Enterprise value to revenue forward of 10x Genomics, Inc. – NASDAQ:TXG - TradingView
10x Genomics Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
10x Genomics $TXG Shares Sold by Renaissance Technologies LLC - MarketBeat
10 X Genomics Inc Stock (TXG) Financials Data
Revenue
Net Income
Cash Flow
EPS
10 X Genomics Inc Stock (TXG) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Saxonov Serge | Chief Executive Officer |
Jun 22 '26 |
Sale |
34.44 |
30,000 |
1,033,269 |
1,108,380 |
| SULIMAN SHEHNAAZ | Director |
Jun 16 '26 |
Sale |
32.63 |
5,723 |
186,756 |
31,722 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):